Israel
tests 4th COVID vaccine dose, awaits ministry green
light
Send a link to a friend
[December 27, 2021]
RAMAT GAN, Israel (Reuters) - An Israeli
hospital administered fourth COVID-19 vaccine doses on Monday to a test
group, as the country considers approving the measure for vulnerable
populations in a bid to outpace a surge in infections fuelled by the
Omicron variant.
|
The Sheba Medical Centre study in Ramat Gan outside Tel Aviv "will
zero in on efficacy of the vaccine in producing antibodies, and
safety, in order to ascertain if a fourth vaccine is needed in
general," a spokesman said. The 150 subjects are all medical staff.
A Health Ministry expert panel last week recommended that Israel
become the first country to offer a fourth vaccine dose - also known
as a second booster - to those aged over 60, those suffering from
compromised immune systems, and medical workers.
The proposal was welcomed by the Israeli government, which has
struggled against a plateauing of turn-out for vaccines.
But the fourth shot awaits final approval by the ministry's
director-general, Nachman Ash, a medical doctor whose decision,
officials say, will be made without government intervention.
Given concern about the lack of test data, Ash may amend the
eligibility criteria by raising the age threshold to 70 and dropping
medical workers from the roster, Israeli media said.
[to top of second column] |
The Health Ministry has neither confirmed nor
denied that, nor said when Ash's decision is
due.
Some 63% of Israel's 9.4 million population have
received the first two vaccine doses, according
to ministry data. Almost 45% have also received
a third dose, or booster shot. Close to 2,000
confirmed or suspected Omicron cases have been
logged.
Israel was the fastest country to roll out
initial vaccines a year ago, and became one of
the first to observe that immunity waned over
time, responding with a widespread booster
programme.
(Writing by Dan Williams; Editing by Peter
Graff)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
|